Berubicin was granted Orphan Drug Designation by FDA for the treatment of malignant gliomas.
Berubicin is sponsored by CNS Pharmaceuticals Inc.
In the phase I trial of Berubicin to treat glioblastoma under a prior developer, 44% of the patients demonstrated a significant improvement in progression-free survival, and one patient experienced a complete response.
Multiple components of the healthcare and public health systems are currently under scrutiny. One of them is reportedly the U.S. Preventive Services Task Force (USPSTF: “Task Force”), established in 1984 and managed by the Agency for Healthcare Research and Quality. It was created to maintain an ongoing evaluation of disease prevention and screening interventions that...
